Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06329453 · ClinicalTrials.gov registry record
Intestinal Immunity in Neurologic Disease
A clinical trial of Multiple Sclerosis and Parkinson Disease, sponsored by Yale University.
- Recruiting
- Registry status
- 100
- Enrollment target
- 1
- Study location
NCT06329453: Recruiting study of Multiple Sclerosis and Parkinson Disease, sponsored by Yale University.
NCT06329453 is a study of Multiple Sclerosis and Parkinson Disease that is actively recruiting participants, run by Yale University. The registered enrollment target is 100 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06329453, a study of Multiple Sclerosis and Parkinson Disease, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to ascertain the functional profiles of the immune cells within the gastrointestinal tract and to determine how these cells contribute to autoimmune and neurologic diseases.
Primary Outcome
Gastrointestinal mucosa cells will be characterized using sRNA measured through high-throughput sequencing with quantitative polymerase chain reaction (qPCR) validation.
Conditions Studied
Interventions
- PROCEDURE Colon Tissue Biopsy
Study Locations (1)
Connecticut
- Yale MS Clinic - North Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2022-08-02 |
| Est. Completion | 2027-08-31 |
What NCT06329453 shows while recruiting
NCT06329453 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (83% lower).
The record links to 3 conditions, with Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which Colon Tissue Biopsy is the first listed.
NCT06329453 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT06329453 about?
NCT06329453 is a clinical study titled "Intestinal Immunity in Neurologic Disease". The purpose of this study is to ascertain the functional profiles of the immune cells within the gastrointestinal tract and to determine how these cells contribute to autoimmune and neurologic diseases.
What is the current status of trial NCT06329453?
This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2022-08-02. Estimated completion is 2027-08-31.
What conditions does trial NCT06329453 study?
This clinical trial studies the following conditions: Multiple Sclerosis, Parkinson Disease, REM Sleep Behavior Disorder.
What interventions are being tested in trial NCT06329453?
The interventions under investigation include: Colon Tissue Biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT06329453?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06329453 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06329453's enrollment target sits among peer trials
100 128th of 315 higher than 181 of 315 other Multiple Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
Prepare the Mind: Can Coaching in Goal-directed Behaviour Increase the Success of Cognitive Rehabilitation in People With MS?
RECRUITING · NA
-
Incremental Vestibulo-ocular Reflex Adaptation as a Novel Treatment for Dizziness in People With Multiple Sclerosis
RECRUITING · NA
-
Vancomycin Study in Multiple Sclerosis (MS)
RECRUITING · Phase 1
-
IConquerMS™ - a Patient-Powered Research Network for Multiple Sclerosis
RECRUITING
-
Prospective Investigation of Multiple Sclerosis in the Three Rivers Region
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI